CII
ENTA icon

CR Intrinsic Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

CR Intrinsic Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-20,000
Closed -$458K – 294
2013
Q3 		$458K Buy
+20,000
New +$382K 0.01% 334

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AP
AlpInvest Partners Amsterdam, Netherlands $49.7M AUM 23.93% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CR Intrinsic Investors's ENTA Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2013, closing a stake of 20,000 shares — an estimated $458K sold.

CR Intrinsic Investors first reported a position in ENTA in Q3 2013 and held it in 1 quarter. The position peaked at $458K in Q3 2013. 66 funds tracked by Wall St. Rank hold ENTA as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Enanta Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 20,000 Enanta Pharmaceuticals shares in Q4 2013, an estimated $458K.
  • CR Intrinsic Investors first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Enanta Pharmaceuticals position peaked at $458K in Q3 2013.
  • 66 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.